Mobile website
Archive > Volume 29 Issue 11 > 2022,29(11):978-984. DOI:10.3872/j.issn.1007-385X.2022.11.003 Prev Next
Expert Forum
Multidisciplinary management on broad-spectrum toxicity and severe toxicity caused by immune checkpoint inhibitors
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
As a new type of immunotherapy, immune checkpoint inhibitors (ICIs) is another emerging anti-tumor treatment modality after chemotherapy, targeted therapy, and anti-angiogenic therapy, and has brought significant survival benefits to patients with malignant tumors. However, the overall incidence of immune-related adverse events (irAEs) is 79%-82%, and irAEs greatly affect clinical treatment decisions and to some extent limit their clinical application and sustained patient benefit. Almost all organ systems can be affected by irAEs, and their universality, specificity, complexity, and diversity lead to great difficulty in diagnosis and treatment. Adequate recognition and early identification of severe irAEs is particularly important to avoid critical toxicity-related deaths, and therefore critical irAEs require treatment by a multidisciplinary team (MDT). Patients with irAEs of unknown diagnosis, critical condition, poor treatment effect, or whether to restart immunotherapy after toxic remission need standardized and standardized MDT treatment. Therefore, establishing a patient-centered irAEs-MDT model to address critical and difficult irAEs based on evidence-based medicine and guideline consensus will maximize the benefits of immunotherapy for oncology patients.
Keywords:
Project Supported:
Clc Number:
